Second-line tisagenlecleucel renders no EFS benefit in aggressive B-cell lymphoma

The anti-CD19 chimeric antigen receptor (CAR) T-cell treatment tisagenlecleucel did not improve event-free survival (EFS) compared with standard care in patients refractory or who had progressed following first-line therapy for aggressive B-cell non-Hodgkin’s lymphoma, results of the phase III BELINDA trial showed.

Which AECOPD patients are likely to test positive for flu?
In patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD), higher body temperature and heart rate, along with low white cell counts, are strong predictors of testing positive for influenza, according to a recent Singapore study.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in